Primary Membranous NephropathyPhase 1/2NCT07765537
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy
A Phase 1/2 study testing FKC289 injection in people with Primary Membranous Nephropathy, run by Shenzhen Fosun Kairos Biotechnology Co., Ltd. at 8 sites in China.
Trial summary
This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory Primary Membranous Nephropathy.The primary objectives are to assess the safety of FKC289 and to establish the recommended Phase II dose (RP2D).And this Phase II study is designed to evaluate the efficacy… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Primary Membranous Nephropathy
- What is being tested?
- FKC289 injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 55 participants
- Where
- 8 sitesChina
- Study dates
- Aug 2026to Mar 2030
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Voluntarily signed the informed consent form (ICF);
- Aged between 18-70 years old (inclusive);
- Histologically confirmed diagnosis of primary membranous nephropathy by renal biopsy obtained within the past 2 years.;
- Relapsed or refractory disease;
- Anti-PLA2R antibody > 50 RU/mL;
- 24-hour urine protein > 3.5 g at screening;
- No active systemic infection (e.g., infectious pneumonia, pulmonary tuberculosis) within 2 weeks prior to leukapheresis;
- Adequate bone marrow and major organ function (including hepatic, renal, cardiac, and pulmonary);
Who cannot join
- Secondary membranous nephropathy or patients with a prior diagnosis of other renal diseases;
- Presence of any clinically significant cardiovascular disease within 6 months prior to screening;
- Clinically significant central nervous system (CNS) disease or pathological abnormality;
- History of solid organ transplantation (e.g., heart, lung, kidney, liver);
- Presence of complete intestinal obstruction;
- Moderate to severe pleural effusion or ascites that is difficult to control with conventional treatment and requires continuous catheter drainage;
Trial locations and contacts
8 sites in 1 country. Contact the study team or a site near you to ask about taking part.
8 sites in 1 country
China8 sites
Peking University People's Hospital
Beijing, Beijing Municipality, 100044
Li Zuo, Medical Doctor, 86-010-88326666, zuoli@bjmu.edu.cn
Xiangya Hospital of Central South University
Changsha, Hunan, 410008
Hui Xu，Gan Zhou, Medical Doctor, 86-0731-84327431, 1196824139@qq.com，Zhougan77@163.com
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072
Guisen Li, Medical Doctor, 86-028-87393999, guisenli@163.com
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510080
Wei Chen, Medical Doctor, 86-020-87758853, chenwei99@mail.sysu.edu.cn
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022
Yonggui Wu, MD, +86-0551-62922114, Wuyongguixialiang@163.com
Nanjing General Hospital of Nanjing Military Command
Nanjing, Jiangsu, 210000
Zhihong Liu, Medical Doctor, 86-025-80862311, zhliunj@vip.163.com
Shenzhen People's Hospital
Shenzhen, Guangdong, 518020
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030
Gang Xu, Medical Doctor, 86-027-83665535, xugang@tjh.tjmu.edu.cn
About this study
This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory Primary Membranous Nephropathy.The primary objectives are to assess the safety of FKC289 and to establish the recommended Phase II dose (RP2D).And this Phase II study is designed to evaluate the efficacy of FKC289.The primary objectives are to assess proportion of subjects achieving clinical response (including complete or partial response) at 6 months.
- Conditions
- Primary Membranous Nephropathy
- Being tested
- FKC289 injection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FKC289 injectionDrug
Anti-BCMA/CD19 chimeric antigen receptor autologous T cells
| Study group | Role | What they receive |
|---|---|---|
| FKC289 injection | Experimental | Not described Receives: Drug: FKC289 injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dose-Limiting Toxicity (DLT)
Number of subjects experiencing DLT
Measured: Within 28 days after FKC289 infusion
Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of subjects experiencing AEs and SAEs
Measured: Within 24 months after FKC289 infusion
Replication Competent Lentivirus (RCL)
Number of subjects with positive detection of RCL
Measured: Within 24 months after FKC289 infusion
Secondary outcomes (5)
Clinical response rate
Proportion of subjects achieving clinical response, including complete response (CR) and partial response (PR)
Measured: Within 6 months,12 months, and 24 months after FKC289 infusion
Clinical complete response rate
Proportion of subjects achieving clinical complete response
Measured: Within 6 months,12 months, and 24 months after FKC289 infusion
Immune response rate
Proportion of subjects achieving immune response
Measured: Within 6 months,12 months, and 24 months after FKC289 infusion
Pharmacokinetics (PK)
Levels of CAR-T cells in peripheral blood
Measured: Within 24 months after FKC289 infusion
Pharmacodynamics (PD)
Proportion of CD19+ B cells and BCMA+ plasma cells in peripheral blood; Changes in the levels of cytokines in peripheral blood
Measured: Within 24 months after FKC289 infusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2026
- Study startAug 2026 (estimated)
- Primary completionSep 2028 (estimated)
- Study completionMar 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Primary Membranous NephropathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 55 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shenzhen Fosun Kairos Biotechnology Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07765537
- Sponsor's protocol ID
- FKC289-2025-001
- Status last verified
- Aug 2026
- First submitted
- 11 Aug 2026
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy
- ClinicalTrials.gov ID
- NCT07765537
- Acronym / sponsor ID
- FKC289-2025-001
- Conditions
- Primary Membranous Nephropathy
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 55 participants (estimated)
- Lead sponsor
- Shenzhen Fosun Kairos Biotechnology Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- Aug 2026 (estimated)
- Primary completion
- Sep 2028 (estimated)
- Study completion
- Mar 2030 (estimated)
- First posted
- 14 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory Primary Membranous Nephropathy.The primary objectives are to assess the safety of FKC289 and to establish the recommended Phase II dose (RP2D).And this Phase II study is designed to evaluate the efficacy of FKC289.The primary objectives are to assess proportion of subjects achieving clinical response (including complete or partial response) at 6 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| FKC289 injection | Experimental | Drug: FKC289 injection |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Voluntarily signed the informed consent form (ICF);
- Aged between 18-70 years old (inclusive);
- Histologically confirmed diagnosis of primary membranous nephropathy by renal biopsy obtained within the past 2 years.;
- Relapsed or refractory disease;
- Anti-PLA2R antibody > 50 RU/mL;
Key exclusion criteria (6 listed)
- Secondary membranous nephropathy or patients with a prior diagnosis of other renal diseases;
- Presence of any clinically significant cardiovascular disease within 6 months prior to screening;
- Clinically significant central nervous system (CNS) disease or pathological abnormality;
- History of solid organ transplantation (e.g., heart, lung, kidney, liver);
- Presence of complete intestinal obstruction;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FKC289 injectionAnti-BCMA/CD19 chimeric antigen receptor autologous T cells | Drug | FKC289 injection |
Primary outcome
Dose-Limiting Toxicity (DLT)
Time frame: Within 28 days after FKC289 infusion
Number of subjects experiencing DLT
Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Within 24 months after FKC289 infusion
Number of subjects experiencing AEs and SAEs
Replication Competent Lentivirus (RCL)
Time frame: Within 24 months after FKC289 infusion
Number of subjects with positive detection of RCL
5 secondary outcomes
Clinical response rate
Time frame: Within 6 months,12 months, and 24 months after FKC289 infusion
Clinical complete response rate
Time frame: Within 6 months,12 months, and 24 months after FKC289 infusion
Immune response rate
Time frame: Within 6 months,12 months, and 24 months after FKC289 infusion
Pharmacokinetics (PK)
Time frame: Within 24 months after FKC289 infusion
Pharmacodynamics (PD)
Time frame: Within 24 months after FKC289 infusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Primary Membranous Nephropathy
Active, not recruitingPhase 1/2
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Lupus Nephritis, Immunoglobulin A Nephropathy
RecruitingPhase 2
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
Primary Membranous Nephropathy
RecruitingPhase 2
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
Primary Membranous Nephropathy
RecruitingPhase 2/3
Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy
Membranous Nephropathy
Not yet recruitingPhase 2
A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease
Primary Membranous Nephropathy, Minimal Change Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing FKC289 injection in people with Primary Membranous Nephropathy, run by Shenzhen Fosun Kairos Biotechnology Co., Ltd. at 8 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Muran Cheng (+86-18252113973, muran.cheng@fosunkairos.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dose-Limiting Toxicity (DLT) (time frame: Within 28 days after FKC289 infusion). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.